Literature DB >> 2332248

Selection of antibiotics for treatment and prophylaxis of staphylococcal infections in cystic fibrosis patients.

A Bauernfeind1, B Przyklenk, C Matthias, R Jungwirth, R M Bertele, K Harms.   

Abstract

Susceptibility in vitro of 179 staphylococcal strains from 107 cystic fibrosis patients against 31 antibiotics indicates that only teicoplanin, vancomycin and netilmicin were active against all strains. The use of betalactam antibiotics is impaired by 11.7% of methicillin-resistant strains. The bactericidal kinetics of cephalexin and flucloxacillin as determined in a pharmacodynamic model demonstrates the killing of strains resistant to cephalexin (MIC 8 mg/l to 32 mg/l) by flucloxacillin. For the rational selection of antistaphylococcal antibiotics for cystic fibrosis patients, both the MIC of the isolates and the concentration of the antibiotics in cystic fibrosis patients have to be considered.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2332248     DOI: 10.1007/bf01641436

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

Review 1.  Clinical significance of Staphylococcus aureus in cystic fibrosis.

Authors:  M I Marks
Journal:  Infection       Date:  1990 Jan-Feb       Impact factor: 3.553

2.  A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis.

Authors:  V A Loening-Baucke; E Mischler; M G Myers
Journal:  J Pediatr       Date:  1979-10       Impact factor: 4.406

3.  [Pharmacokinetics of cephalexin in adults and children].

Authors:  C Simon; G Sievers; H J Rohwedder; V Malerczyk
Journal:  Dtsch Med Wochenschr       Date:  1970-10-16       Impact factor: 0.628

Review 4.  High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients.

Authors:  F Sörgel; U Stephan; H G Wiesemann; B Gottschalk; C Stehr; M Rey; H B Böwing; H C Dominick; M Geldmacher von Mallinckrodt
Journal:  Infection       Date:  1987       Impact factor: 3.553

5.  Antistaphylococcal antibodies in cystic fibrosis.

Authors:  B Strandvik; A Hollsing; R Möllby; M Granström
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

6.  Simultaneous simulation of the serum profiles of two antibiotics and analysis of the combined effect against a culture of Pseudomonas aeruginosa.

Authors:  A Bauernfeind; R Jungwirth; C Petermüller
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

7.  Microbiologic and therapeutic aspects of Staphylococcus aureus in cystic fibrosis patients.

Authors:  A Bauernfeind; G Hörl; B Przyklenk
Journal:  Scand J Gastroenterol Suppl       Date:  1988

8.  Antimicrobial chemotherapy in patients with cystic fibrosis.

Authors:  J P Guggenbichler; J Schneeberger
Journal:  Infection       Date:  1987       Impact factor: 3.553

9.  Staphylococcus aureus in patients with cystic fibrosis: an epidemiological analysis using a combination of traditional and molecular methods.

Authors:  R V Goering; A Bauernfeind; W Lenz; B Przyklenk
Journal:  Infection       Date:  1990 Jan-Feb       Impact factor: 3.553

  9 in total
  4 in total

1.  [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins].

Authors:  A Bauernfeind; R Jungwirth; S Schweighart; M Theopold
Journal:  Infection       Date:  1990       Impact factor: 3.553

2.  Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.

Authors:  A Bauernfeind; R Jungwirth
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

Review 3.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

4.  Epidemiology of Staphylococcus aureus in patients with cystic fibrosis.

Authors:  C Branger; J M Fournier; J Loulergue; A Bouvet; P Goullet; A Boutonnier; C de Gialluly; G Couetdic; M Chomarat; M C Jaffar-Banjee
Journal:  Epidemiol Infect       Date:  1994-06       Impact factor: 2.451

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.